With this expansion, the laboratories will form a centre of excellence for fully integrated active pharmaceutical ingredients (API) and formulation development services, including pre-formulation studies, prototype formulation development, process development and optimisation, Dr Reddy’s said.
CPS, a strategic business unit of Dr Reddy's, is the second largest API supplier globally, and can develop and manufacture APIs rapidly across the entire product life.
Also Read
These development capabilities will seamlessly integrate CPS’ offerings of cGMP supplies for clinical trials, registration batches and commercial manufacture, company claimed.
“This new centre of excellence for formulation development services reflects our ongoing focus to better serve our pharma customers. Access to our integrated expertise and resources will bring their drug product to market in an even quicker and more cost-efficient manner than before,” Anurag Roy, vice president, global business head at Dr Reddy’s CPS, stated in a release on Tuesday.